CMAB007
As of the edition of 20 October 2026, CMAB007 is a drug known only by a code name: in active development; acts on IGHE.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2024
- Kind
- Code name only
- Registered trials
- 3, 0 stopped early
- Disease areas
- Immune system; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IGHE | Immunoglobulin heavy constant epsilon | P01854 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 1 | 1 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Biomabs Pharmaceutical | Lead sponsor of trials | 2018 to now |
| Taizhou Mabtech Pharmaceutical | Lead sponsor of trials | 2022 to now |